COVID-19：铜和 N-乙酰半胱氨酸（NAC）在联合使用候选抗病毒药物治疗 SARS-CoV-2 中的潜在作用。
COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2.
机构信息
Pharmaceutical Services, Ministry of Health of the Republic of Cyprus, Nicosia, Cyprus
National Organization for Medicines, Athens, Greece
出版信息
In Vivo. 2020 Jun;34(3 Suppl):1567-1588. doi: 10.21873/invivo.11946.
BACKGROUND
On March 11, 2020, the World Health Organization (WHO) declared the outbreak of coronavirus disease (COVID-19) a pandemic. Since then, thousands of people have suffered and died, making the need for a treatment of severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) more crucial than ever.
MATERIALS AND METHODS
The authors carried out a search in PubMed, ClinicalTrials.gov and New England Journal of Medicine (NEJM) for COVID-19 to provide information on the most promising treatments against SARS-CoV-2.
RESULTS
Possible COVID-19 agents with promising efficacy and favorable safety profile were identified. The results support the combination of copper, N-acetylcysteine (NAC), colchicine and nitric oxide (NO) with candidate antiviral agents, remdesivir or EIDD-2801, as a treatment for patients positive for SARS-CoV-2.
CONCLUSION
The authors propose to study the effects of the combination of copper, NAC, colchicine, NO and currently used experimental antiviral agents, remdesivir or EIDD-2801, as a potential treatment scheme for SARS-COV-2.
背景
2020 年 3 月 11 日，世界卫生组织（WHO）宣布冠状病毒病（COVID-19）爆发为大流行。从那时起，成千上万的人遭受病痛折磨甚至死亡，因此，对于严重急性呼吸综合征相关冠状病毒-2（SARS-CoV-2）的治疗方法的需求比以往任何时候都更加迫切。
材料和方法
作者在 PubMed、ClinicalTrials.gov 和新英格兰医学杂志（NEJM）上搜索了 COVID-19 相关信息，以提供针对 SARS-CoV-2 最有前途的治疗方法的信息。
结果
确定了一些可能具有良好疗效和安全性的 COVID-19 候选药物。这些结果支持将铜、N-乙酰半胱氨酸（NAC）、秋水仙碱和一氧化氮（NO）与候选抗病毒药物瑞德西韦或 EIDD-2801 联合用于治疗 SARS-CoV-2 阳性患者。
结论
作者建议研究铜、NAC、秋水仙碱、NO 与目前使用的实验性抗病毒药物瑞德西韦或 EIDD-2801 联合使用的效果，作为 SARS-COV-2 的潜在治疗方案。
Zotero 插件